November 10, 2023: Novo Nordisk plans to invest 42 million Danish kroner ($6 billion) in Denmark to create new capacities for making active pharmaceutical ingredients and expand its portfolio within serious chronic diseases.
A portion of this investment is included in the 25 billion Danish kroner capital expenditure announced in connection with Novo Nordisk’s full-year financial results in February.
The additional amount will be invested through the next six years, according to a company statement.
The new API facility will be designed as a multi-product facility, with flexibility to accommodate current and future processes.
The investment comes as Novo Nordisk marks the 100th anniversary of its founding in Denmark, where more than 23,000 employees still work today.
The company will expand existing manufacturing facilities in Kalundborg, Denmark, for the current and future product portfolio.
The investment will create additional capacity across the entire global value chain from manufacturing of active pharmaceutical ingredients (API) to packaging, with the majority invested in API capacity.
The investment, which includes GLP-1 products or glucagon-like peptide-1 amino acid, peptide hormone, will increase Novo Nordisk’s ability to meet future market demands.
“The significant investment announced today confirms the importance of utilising our existing sites, including in Denmark, as cornerstones for not only the growth we see but also to expand as fast as possible by utilising all the infrastructure, knowledge and competencies we already have,” said Henrik Wulff, executive vice president, Product Supply, Quality & IT, Novo Nordisk.
“Our continued investment in global capacity demonstrates the belief we have in our current and future product portfolio and its relevance for people living with serious chronic diseases.”
The new API facility will have a footprint of 170,000 m2. The construction projects will be finalised gradually from the end of 2025 through 2029.